On 21 July 2025, the Court of Appeal delivered a significant ruling in AstraZeneca AB & Anor v Generics (UK) Limited & Ors, ...

Included in the open-label crossover SOGALDI-PEF study were adults with symptomatic heart failure (New York Heart Association ...

Dapagliflozin was well tolerated among patients with an eGFR of less than 60 mL/minute per 1.73² and among those with an eGFR of greater than or equal to 60 mL/minute per 1.73².

Dapagliflozin was found to be more effective at preventing hospitalizations for patients 65 years or younger compared with those older than 65 years.

The judgement, delivered on 16 July 2025, upheld the High Court's April 2025 ruling that declared AstraZeneca's dapagliflozin patent invalid for lack of inventive step and insufficiency. The central ...

The Maryland Prescription Drug Affordability Board (PDAB) found that Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga (dapagliflozin) present affordability ...

India accounts for 1 in 7 adults living with diabetes globally. An estimated 89.8 million adults aged 20-79 years in India ...

Dapagliflozin was well tolerated and the rate of treatment discontinuation was low in patients with and without diabetes. Hypoglycemia and diabetic ketoacidosis developed only in patients with ...

A new clinical trial shows that combining dapagliflozin with insulin improves kidney health and blood sugar control, and ...

Results from clinical trials show that patients receiving dapagliflozin in combination with other OADs had A1C reductions in the range of —0.4% to –1.2% at 1 year. 6,7,22,23 Our study found ...

PHILADELPHIA, PA—Dapagliflozin (Farxiga; AstraZeneca), originally developed for the treatment of type 2 diabetes, has a broad, positive impact across various subsets of patients with chronic heart ...

AstraZeneca Plc's (NASDAQ: AZN) dapagliflozin 5mg (Forxiga/Farxiga) was authorized in 2019 as an adjunct to insulin in patients with type 1 diabetes with a body-mass index (BMI) of 27 kg per m2.